, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=170628&from=4 CLASS PERIOD: March 4, 2024 to May 23, 2025 ALLEGATIONS: The c ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Savara To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruq ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Savara To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212- 983-9330Â (Ext. 1310). [You may also click here for additional information] , /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading nationa ...

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI (a clinical trial for the treatment of a rare lung disease) Biologics License Application ("BLA") lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly, the FDA was unlikely to approve the MOLBREEVI BLA in its current form; (3) the foregoing made it unlikely that Savara would complete submission of the MO ...

Accessibility StatementSkip Navigation The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by th ...

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission ...

Core Viewpoint - Investors in Savara Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged undisclosed information regarding the company's regulatory submissions and business prospects [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that between March 7, 2024, and May 23, 2025, Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient details on its chemistry, manufacturing, and controls [2]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. - The lawsuit asserts that the positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Participation Information - Investors who suffered losses on their Savara investments are encouraged to participate in the lawsuit before the lead plaintiff deadline of November 7, 2025 [2]. - Interested parties can contact Glancy Prongay & Murray LLP for more information or to learn about their rights regarding the lawsuit [3][4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities during the specified class period of the upcoming lead plaintiff deadline on November 7, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Savara securities between March 7, 2024, and May 23, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the November 7, 2025 deadline [2]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Savara's defendants made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [4]. - It is claimed that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital, and that the public statements made by the defendants were materially false and misleading [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit related to misleading statements about the company's drug application process for MOLBREEVI BLA [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 4, 2024, to May 23, 2025, Savara Inc. made materially false and misleading statements regarding the MOLBREEVI BLA treatment for pulmonary alveolar proteinosis [3]. - Specific allegations include a lack of sufficient information about MOLBREEVI's chemistry, manufacturing, and controls, which made FDA approval unlikely in its current form [3]. - The delay in regulatory approval raised concerns that Savara would need to raise additional capital, contradicting the company's public statements [3]. Group 2: Class Action Details - Shareholders who purchased shares of SVRA during the specified class period are encouraged to register for the class action, with a deadline of November 7, 2025, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit due to alleged misleading statements related to the approval of the MOLBREEVI BLA treatment for pulmonary alveolar proteinosis [1]. Summary by Sections Allegations - The complaint alleges that during the class period from March 4, 2024, to May 23, 2025, Savara Inc. made materially false and misleading statements regarding the MOLBREEVI BLA, including: - Lack of sufficient information about MOLBREEVI's chemistry, manufacturing, and controls [1]. - Unlikelihood of FDA approval for the MOLBREEVI BLA in its current form [1]. - Delay in submission of the MOLBREEVI BLA within the previously represented timeframe [1]. - Increased likelihood of needing to raise additional capital due to regulatory approval delays [1]. - Overall, the public statements made by the defendants were materially false and misleading throughout the relevant period [1]. Next Steps for Shareholders - Shareholders who purchased shares of Savara Inc. during the specified class period are encouraged to register for the class action by November 7, 2025, to potentially be appointed as lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. Firm's Mission - The Gross Law Firm aims to protect the rights of investors affected by deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3].